Idiopathic Pulmonary Fibrosis Treatment Market
According to Intent Market Research, the Idiopathic Pulmonary Fibrosis Treatment Market is expected to grow from USD 3.7 Billion in 2024-e at a CAGR of 11.7% to touch USD 8.0 Billion by 2030. The Idiopathic Pulmonary Fibrosis Treatment Market is dominated by key players such as, Boehringer Ingelheim, Novartis International AG, Bristol-Myers Squibb, Roche Holding AG, Genentech, Inc., and FibroGen, Inc..